CRISPR Therapeutics (CRSP) PT Raised to $51 at Citi
Tweet
Share
E-mailGet Alerts CRSP Hot Sheet
Price: $59.50 +2.37%
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
Citi raised its price target on CRISPR Therapeutics (NASDAQ: CRSP) to $51.00 (from $20.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi upgrades O-I Glass to Buy with $9 price target, opens 90-Day upside catalyst watch
- Citigroup set to join top banks in Anthropic IPO - Bloomberg
- Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
